Biovest International, Inc. Establishes World Class Scientific Advisory Board Comprised of Key Opinion Leaders in the Fields of Cancer Immunotherapy, Bioinformatics and Cell Culture Systems

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has formally established its Scientific Advisory Board (SAB) comprised of key opinion leaders from prestigious institutions including the MD Anderson Cancer Center, the Abramson Cancer Center at the University of Pennsylvania, the University of Michigan Medical School and the H. Lee Moffitt Cancer Center. Dedicated to the advancement of cancer vaccines, the Biovest SAB represents a group of preeminent physicians and doctors from the fields of cancer immunotherapy, immunology, bioinformatics, regulatory affairs and cell culture bio-manufacturing.

MORE ON THIS TOPIC